In Vivo Antigen Programming Services for Universal CAR-T Targeting (BROAD-CAR)

Q: Q1: How does BROAD-CAR differ from traditional CAR-T?

A1: While conventional CAR-T therapies depend on ex vivo cell manipulation and individualized manufacturing, BROAD-CAR enables direct in situ reprogramming of endogenous T cells through a minimally invasive injection. This streamlined approach reduces production timelines, lowers costs, and simplifies logistical complexity, making advanced immunotherapy more accessible.

Online Inquiry

Background Service Service Packages Workflow Highlights FAQs Contact

The development of CAR-T therapies is often constrained by extended drug development cycles, high manufacturing costs associated with ex vivo cell manipulation, and the logistical complexities of patient-specific leukapheresis. Creative Biolabs' In vivo Antigen Programming for Universal CAR-T Targeting (BROAD-CAR) overcomes these barriers by leveraging innovative targeted mRNA-LNP delivery and modular universal receptor engineering to enable in vivo antigen programming. This service provides a platform to generate high-quality, "off-the-shelf" therapeutic responses, eliminating the need for individualized cell manufacturing. By streamlining clinical trial processes and reducing costs, BROAD-CAR accelerates drug discovery and facilitates more scalable, accessible CAR-T therapies.

Introduction

BROAD-CAR is an innovative platform technology that achieves universal CAR-T cell targeting through the in vivo reprogramming of solid tumor antigens. This In vivo Antigen Programming for Universal CAR-T Targeting functions by utilizing engineered bacterial outer membrane vesicles to uniformly label heterogeneous tumor cells with a synthetic tag while simultaneously modulating the immunosuppressive microenvironment, thereby enabling a single CAR-T specificity to effectively eradicate solid tumors regardless of their native antigen expression.

Fig.1 BROAD-CAR: in vivo antigen reprogramming enabling universal CAR-T therapy. (Creative Biolabs Original) Fig.1 Universal CAR-T targeting via in vivo antigen programming.

In Vivo Antigen Programming for Universal CAR-T Targeting (BROAD-CAR) at Creative Biolabs

Creative Biolabs offers an integrated solution portfolio to accelerate the shift from early-stage research toward clinical application. Utilizing the BROAD-CAR platform, our services overcome the conventional limitations of patient-specific manufacturing by enabling direct in situ reprogramming of endogenous T cells. This approach provides the essential molecular framework for a single universal CAR-T construct to engage multiple antigens via programmable adapter molecules.

Service Packages

Enhanced Membrane Fusion & Delivery Platforms for CAR-T Target Induction

We utilize proprietary membrane fusion platforms to transiently display universal CAR-targeting antigens directly on tumor cells in vivo, converting otherwise unrecognized cancer cells into clear targets for BROAD-CAR therapy. This technology enables controlled, tumor-localized antigen expression without the need for genetic modification of cancer cells, supporting applications in solid tumors with heterogeneous antigen expression and providing a universal switch for CAR-T engagement.

Learn More →

Quantification of Induced Antigen Density & CAR-T Activation Thresholds

We leverage quantitative flow cytometry and imaging platforms to precisely measure antigen density on engineered tumor cells and determine the minimum threshold required for BROAD-CAR activation. This platform enables predictive modeling of CAR-T responses against varying antigen levels, facilitating rational selection of target antigens and optimization of CAR designs for enhanced sensitivity against low-density tumors while minimizing off-tumor reactivity.

Learn More →

Our Service Process

Required Starting Materials: Clients initiate a collaboration by providing the genetic sequence for the target scFv/ligand, specifications for the target cell population, and the desired delivery modality, including LNP or viral vectors.

Key Steps:

Workflow of in vivo antigen programming for universal CAR-T targeting at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: Upon project completion, clients obtain fully characterized delivery constructs and an analytical quality control report documenting transduction efficiency and functional potency.

Key Advantages

Overcoming Antigen Heterogeneity: This platform enables the targeting of a uniform, engineered "tag" rather than native tumor antigens, allowing a single CAR-T specificity to eliminate a diverse population of tumor cells regardless of their original antigen expression profile.
Reversing T-Cell Exhaustion in the TME: By precisely blocking the PD-1/PD-L1 checkpoint axis within the tumor microenvironment, the platform preserves CAR-T cell effector function and prevents the premature exhaustion typically induced by solid tumors.
Engineering a Versatile, Multi-Functional Delivery System: The use of engineered bacterial outer membrane vesicles (OMVs) provides a modular platform capable of simultaneously delivering antigen-labeling agents and immune-modulating signals directly to the tumor site.

FAQs

Q1: How does BROAD-CAR differ from traditional CAR-T?

A1: While conventional CAR-T therapies depend on ex vivo cell manipulation and individualized manufacturing, BROAD-CAR enables direct in situ reprogramming of endogenous T cells through a minimally invasive injection. This streamlined approach reduces production timelines, lowers costs, and simplifies logistical complexity, making advanced immunotherapy more accessible.

Q2: Can I target multiple antigens with one BROAD-CAR construct?

A2: Absolutely. Our universal receptor architecture decouples antigen recognition from CAR signaling, allowing you to achieve multi-antigen targeting simply by administering different adapter molecules, such as biotinylated antibodies, without re-engineering the underlying CAR construct. This modular design provides exceptional flexibility for addressing tumor heterogeneity and antigen escape.

Why Choose Us

Partnering with Creative Biolabs means engaging a pioneer at the forefront of synthetic immunology. Our BROAD-CAR platform is strategically engineered to address the complexities of oncology and to enable immune resets in autoimmune disorders. Leveraging cutting-edge advances in targeted lipid nanoparticle technology, we enable therapeutic delivery as a straightforward intravenous infusion, effectively circumventing the requirement for lymphodepleting preconditioning regimens.

How to contact us?

Creative Biolabs delivers a cutting-edge platform, harnessing the patient's own physiology as a living bioreactor for therapeutic production. By circumventing conventional ex vivo manufacturing workflows, we offer a robust, safe, and scalable approach to next-generation immunotherapy. Reach out to our team today to explore how BROAD-CAR can accelerate your program.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.